Enliven Therapeutics, Inc. (ELVN) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Boulder, CO, 美国. 现任CEO为 Richard A. Fair.
ELVN 拥有 IPO日期为 2020-03-12, 62 名全职员工, 在 NASDAQ Global Select, 市值为 $2.63B.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
